Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals [NA]

View source ↗

Summary

A randomized, double-blind, placebo-controlled clinical trial evaluating CLB101 for gut health in healthy overweight adults is currently enrolling by invitation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Disorders
• Obesity
• Overweight

Drugs mentioned

• CLB101

Snippet

Sponsor: ClostraBio Inc. | Conditions: Gastrointestinal, Overweight , Obesity | NA | Status: ENROLLING_BY_INVITATION